ACHN Achillion Pharmaceuticals Inc.

2.99
0  0%
Previous Close 2.99
Open
Price To Book 1.67
Market Cap 414,788,725
Shares 138,725,326
Volume 0
Short Ratio
Av. Daily Volume 1,193,449

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

End of Phase 2 meeting 4Q 2019.
ACH-4471
C3 glomerulopathy (C3G)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178
Hepatitis C (HCV)
Phase 2 final data presented at EHA June 15, 2019.
ACH-4471
Paroxysmal nocturnal hemoglobinuria (PNH)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178 - OMEGA-1
Hepatitis C (HCV)
End of Phase 2 meeting 4Q 2019.
ACH-4471
C3 glomerulopathy (C3G)
Phase 1 multiple ascending dose trial to be completed 2019.
ACH-5228
Healthy volunteers

Latest News

  1. Achillion to Present at the JMP Securities Life Sciences Conference
  2. Achillion Announces Upcoming Scientific Presentation at the 24th Congress of the European Hematology Association
  3. Why Is Achillion (ACHN) Down 1.4% Since Last Earnings Report?
  4. The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering
  5. Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting
  6. Achillion Granted Twentieth Patent for Factor D Portfolio
  7. Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1
  8. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
  9. What You Need to Know About Achillion Pharmaceuticals' Q1 Update
  10. Achillion: 1Q Earnings Snapshot
  11. Achillion Reports First Quarter 2019 Financial Results
  12. Biotech Bets and a Goodbye from a Favorite Expert
  13. Why Is Achillion (ACHN) Up 25.6% Since Last Earnings Report?
  14. Achillion Meets Enrollment Target in Kidney Disease Studies
  15. Why Achillion Pharmaceuticals Stock Is Jumping Today
  16. Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy
  17. Achillion Completes Enrollment in Rare Blood Disorder Study
  18. Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial
  19. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Are Analysts Right About The Drop In Earnings?
  20. Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4